Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-(n-piperidinyl)-1,1-diphenyl-1-propanol Methanesulfonate
2. 3-piperidino-1,1-diphenylpropanol
3. 3-piperidinyl-1,1-diphenylpropan-1-ol
4. Myoson
5. Pridinol Mesylate
6. Pridinol Monohydrochloride
7. Pridinol Monomesylate
8. Ridinol
1. 511-45-5
2. 1,1-diphenyl-3-(piperidin-1-yl)propan-1-ol
3. Nonplesin
4. Lyseen
5. Parks
6. Parks 12
7. Parks 12 Hommel
8. Pridinolum
9. Nonpressin (free Base)
10. C-238
11. Hh 212
12. 1,1-diphenyl-3-piperidino-1-propanol
13. Alpha,alpha-diphenyl-1-piperidinepropanol
14. 1,1-diphenyl-3-(1-piperidyl)-1-propanol
15. 1-piperidinepropanol, Alpha,alpha-diphenyl-
16. 3-(n-piperidyl)-1,1-diphenyl-1-propanol
17. 238 C
18. Nsc 23016
19. Nsc-23016
20. Nsc23016
21. 9e75q6suub
22. 1,1-diphenyl-3-piperidin-1-ylpropan-1-ol
23. 1,1-diphenyl-3-(1-piperidinyl)-1-propanol
24. Ridinol
25. Chebi:75247
26. Pridinol (inn)
27. Pridinol Mesilate
28. Benzhydrol, .alpha.-(2-piperidinoethyl)-
29. Pridinol [inn]
30. Nsc 23016; Nsc 403797; Nonplesin
31. .alpha.,.alpha.-diphenyl-1-piperidinepropanol
32. Dsstox_cid_25090
33. Dsstox_rid_80664
34. Dsstox_gsid_45090
35. Pridinol [inn:dcf]
36. Pridinolum [inn-latin]
37. 1-piperidinepropanol,.alpha.-diphenyl-
38. Cas-511-45-5
39. Hsdb 2684
40. Einecs 208-128-0
41. Unii-9e75q6suub
42. Benzhydrol, Alpha-(2-piperidinoethyl)-
43. Brn 0252983
44. A-carotene
45. Spectrum_001320
46. Pridinol [hsdb]
47. Pridinol [mi]
48. Prestwick0_000799
49. Prestwick1_000799
50. Prestwick2_000799
51. Prestwick3_000799
52. Spectrum2_001985
53. Spectrum3_001552
54. Spectrum4_000728
55. Spectrum5_001069
56. Pridinol [who-dd]
57. Ncistruc1_000328
58. Ncistruc2_000375
59. Bspbio_000938
60. Bspbio_003024
61. Kbiogr_000996
62. Kbioss_001800
63. 5-20-02-00247 (beilstein Handbook Reference)
64. Divk1c_000726
65. Schembl143298
66. Spbio_002169
67. Spbio_002877
68. Bpbio1_001032
69. Chembl404215
70. Dtxsid0045090
71. Kbio1_000726
72. Kbio2_001800
73. Kbio2_004368
74. Kbio2_006936
75. Kbio3_002524
76. Ninds_000726
77. Alpha-(2-piperidinoethyl)benzhydrol
78. Nci23016
79. Zinc1482149
80. Tox21_110022
81. Ccg-37974
82. Mfcd00242961
83. Ncgc00013289
84. Nsc403797
85. Akos016001547
86. Tox21_110022_1
87. Db13642
88. Nsc-403797
89. Idi1_000726
90. Ncgc00013289-01
91. Ncgc00013289-02
92. Ncgc00013289-03
93. Ncgc00013289-04
94. Ncgc00013289-05
95. Ncgc00013289-06
96. Ncgc00013289-07
97. Ncgc00013289-09
98. Ncgc00023906-03
99. Ncgc00023906-04
100. Ncgc00023906-05
101. Ac-24366
102. Nci60_001871
103. Sbi-0051765.p002
104. Ab00053638
105. 1,1-diphenyl-3-piperidin-1-yl-propan-1-ol
106. D08418
107. 1,1-diphenyl-3-(1-piperidinyl)-1-propanol #
108. 1-piperidinepropanol, .alpha.,.alpha.-diphenyl-
109. Ab00053638_16
110. Ab00053638_17
111. N-propanol, 1,1-diphenyl-3-(piperidin-1-yl)-
112. Ag-680/20240026
113. Q827515
114. Brd-k17565903-066-05-8
115. Brd-k17565903-066-15-7
Molecular Weight | 295.4 g/mol |
---|---|
Molecular Formula | C20H25NO |
XLogP3 | 3.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 5 |
Exact Mass | 295.193614421 g/mol |
Monoisotopic Mass | 295.193614421 g/mol |
Topological Polar Surface Area | 23.5 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 294 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
/EXPL THER/ A randomized, double-blind, placebo-controlled three-way cross-over study was performed to investigate the effect of two muscle relaxants (tolperisone hydrochloride and pridinol mesilate) on experimental jaw-muscle pain and jaw-stretch reflexes. Fifteen healthy men participated in three randomized sessions separated by at least 1 week. In each session 300 mg tolperisone, 8 mg pridinol mesilate or placebo was administered orally as a single dose. One hour after drug administration 0.3 mL hypertonic saline (5.8%) was injected into the right masseter to produce muscle pain. Subjects continuously rated their perceived pain intensity on an electronic 10-cm visual analogue scale (VAS). The pressure pain threshold (PPT) was measured and short-latency reflex responses were evoked in the pre-contracted (15% maximal voluntary contraction) masseter and temporalis muscles by a standardised stretch device (1 mm displacement, 10 ms ramp time) before (baseline), 1 hr after medication (post-drug), during ongoing experimental muscle pain (pain-post-drug), and 15 min after pain had vanished (post-pain). Analysis of variance demonstrated significantly lower VAS peak pain scores (5.9 +/- 0.4 cm) after administration of tolperisone hydrochloride compared with pridinol mesilate (6.8 +/- 0.4 cm) and placebo (6.6 +/- 0.4 cm) (P=0.020). Administration of pridinol mesilate was associated with a significant decrease in PPTs compared with tolperisone hydrochloride and placebo (P=0.002) after medication, but not after experimental jaw-muscle pain. The normalized peak-to-peak amplitude of the stretch reflexes were not significantly influenced by the test medication (P=0.762), but were in all sessions significantly facilitated during ongoing experimental jaw-muscle pain (P=0.034). In conclusion, tolperisone hydrochloride provides a small, albeit significant reduction in the perceived intensity of experimental jaw-muscle pain whereas the present dose had no effect on the short-latency jaw-stretch reflex. /Tolperisone hydrochloride and pridinol mesilate/
PMID:12935797 Svensson P et al; Eur J Pain 7 (5): 449-56 (2003)
M - Musculo-skeletal system
M03 - Muscle relaxants
M03B - Muscle relaxants, centrally acting agents
M03BX - Other centrally acting agents
M03BX03 - Pridinol
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
Reply
14 Sep 2024
Reply
15 Jun 2023
Reply
28 Mar 2023
Reply
19 Jan 2023
Reply
23 Nov 2022
Reply
17 Nov 2022
Reply
08 Mar 2022
Reply
20 Aug 2021
Reply
29 May 2021
Reply
24 Sep 2020
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?